易瑞生物
(300942)
| 流通市值：21.53亿 | | | 总市值：26.38亿 |
| 流通股本：3.27亿 | | | 总股本：4.01亿 |
| 报告期 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 648,551,039.12 | 229,095,093.36 | 212,068,033.13 | 247,451,094.68 |
| 应收票据及应收账款 | 69,280,288.69 | 61,260,591.72 | 55,672,150.31 | 83,877,942.22 |
| 其中：应收票据 | 257,786 | 22,354 | 60,222 | - |
| 应收账款 | 69,022,502.69 | 61,238,237.72 | 55,611,928.31 | 83,877,942.22 |
| 应收款项融资 | - | - | - | 150,000 |
| 预付款项 | 13,610,203.47 | 21,769,096.26 | 18,149,919.03 | 13,815,060.86 |
| 其他应收款合计 | 19,048,935.69 | 17,096,759.65 | 19,078,145.53 | 15,172,785.35 |
| 存货 | 63,313,211.1 | 68,324,611.01 | 83,337,947.31 | 100,608,210.17 |
| 其他流动资产 | 8,579,969.24 | 92,869,411.05 | 153,343,154.95 | 213,344,217.17 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 822,383,647.31 | 542,567,633.12 | 571,749,100.26 | 674,419,310.45 |
| 非流动资产: | | | | |
| 长期股权投资 | 191,529,017.11 | 192,887,867.12 | 192,039,105.64 | 195,757,730.69 |
| 固定资产 | 91,855,129.59 | 88,648,406.9 | 83,751,948.56 | 83,985,636.2 |
| 在建工程 | 273,324,764.55 | 247,957,020.32 | 203,798,319.54 | 190,866,774.16 |
| 使用权资产 | 19,955,636.08 | 23,348,354.49 | 44,719,805.67 | 49,788,389.7 |
| 无形资产 | 41,246,587.42 | 41,659,809.19 | 41,928,935 | 42,400,263.77 |
| 长期待摊费用 | 12,332,854.34 | 7,233,465.68 | 10,978,611.32 | 14,304,446.88 |
| 递延所得税资产 | 19,288,913.9 | 29,222,462.83 | 20,369,798.78 | 14,903,300.37 |
| 其他非流动资产 | 3,402,108.82 | 9,800,667.46 | 33,572,204.71 | 16,029,749.52 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 652,935,011.81 | 640,758,053.99 | 631,158,729.22 | 608,036,291.29 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 1,475,318,659.12 | 1,183,325,687.11 | 1,202,907,829.48 | 1,282,455,601.74 |
| 流动负债: | | | | |
| 应付票据及应付账款 | 48,792,150.05 | 58,741,550.96 | 63,061,338.39 | 65,107,112.08 |
| 应付账款 | 48,792,150.05 | 58,741,550.96 | 63,061,338.39 | 65,107,112.08 |
| 预收款项 | 1,903.48 | - | 83,595.29 | - |
| 合同负债 | 33,020,421.66 | 31,518,346.44 | 31,374,796.78 | 66,613,643.52 |
| 应付职工薪酬 | 20,078,859.97 | 18,836,367.24 | 16,462,662.78 | 31,474,241.33 |
| 应交税费 | 1,669,075.38 | 8,408,536.05 | 7,628,555.52 | 5,795,443.46 |
| 其他应付款合计 | 7,998,878.68 | 5,868,573.23 | 3,135,304.53 | 4,142,497.24 |
| 一年内到期的非流动负债 | 19,371,391.95 | 20,190,171.88 | 24,176,402.89 | 23,774,923.55 |
| 其他流动负债 | 1,802,551.23 | 1,742,210.58 | 1,716,766.07 | 2,875,639.61 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 132,735,232.4 | 145,305,756.38 | 147,639,422.25 | 199,783,500.79 |
| 非流动负债: | | | | |
| 长期借款 | 120,648,882.19 | 102,791,120.59 | 56,232,830 | 56,320,000 |
| 应付债券 | 239,591,914.67 | - | - | - |
| 租赁负债 | 11,028,460.15 | 13,932,191.21 | 33,923,665.11 | 39,245,766.95 |
| 预计负债 | 2,080,000 | 2,080,000 | 2,080,000 | 2,080,000 |
| 递延收益 | 20,875,408.36 | 22,053,987.73 | 22,176,404.23 | 20,325,191.14 |
| 递延所得税负债 | - | - | 108,506.86 | - |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 394,224,665.37 | 140,857,299.53 | 114,521,406.2 | 117,970,958.09 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 526,959,897.77 | 286,163,055.91 | 262,160,828.45 | 317,754,458.88 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 400,860,000 | 400,860,000 | 400,860,000 | 400,860,000 |
| 其他权益工具 | 81,650,739.83 | - | - | - |
| 资本公积 | 186,581,963.3 | 186,581,963.29 | 182,009,649.07 | 178,695,399.06 |
| 其他综合收益 | 1,708,278.37 | 2,622,166.44 | 693,449.48 | -94,974.69 |
| 盈余公积 | 53,580,647.83 | 53,580,647.83 | 53,580,647.83 | 53,580,647.83 |
| 未分配利润 | 224,193,350.21 | 253,719,611.41 | 303,789,021.5 | 331,850,136.53 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 948,574,979.54 | 897,364,388.97 | 940,932,767.88 | 964,891,208.73 |
| 少数股东权益 | -216,218.19 | -201,757.77 | -185,766.85 | -190,065.87 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 948,358,761.35 | 897,162,631.2 | 940,747,001.03 | 964,701,142.86 |
| 负债和股东权益合计 | 1,475,318,659.12 | 1,183,325,687.11 | 1,202,907,829.48 | 1,282,455,601.74 |
| 公告日期 | 2023-10-27 | 2023-08-30 | 2023-04-26 | 2023-04-26 |
| 审计意见(境内) | | | | 标准无保留意见 |